Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
YL Verschoor, J van de Haar, JG van den Berg… - Nature medicine, 2024 - nature.com
Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite
recent advancements, most patients die of their disease. Although immune checkpoint …
recent advancements, most patients die of their disease. Although immune checkpoint …